Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MC4R | P32245 | 2/20 | 0.71 |
| ▸ | MC5R | P33032 | 2/20 | 0.71 |
| ▸ | MC3R | P41968 | 2/20 | 0.71 |
| ▸ | MC1R | Q01726 | 2/20 | 0.71 |
| ▸ | CXCR4 | P61073 | 9/20 | 0.66 |
| ▸ | PTH1R | Q03431 | 5/20 | 0.62 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.62 |
| ▸ | AKT1 | P31749 | 1/20 | 0.60 |
| ▸ | GLP1R | P43220 | 2/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cosyntropin SCHEMBL15960130 | 0.90 | MC4R (0.81) | MC4RMC5RMC3RMC1RCXCR4 | |
| Cosyntropin SCHEMBL33367 | 0.90 | MC4R (0.81) | MC4RMC5RMC3RMC1RCXCR4 | |
| Cosyntropin SCHEMBL29410267 | 0.90 | MC4R (0.81) | MC4RMC5RMC3RMC1RCXCR4 | |
| SCHEMBL29519503 | 0.90 | MC4R (0.81) | MC4RMC5RMC3RMC1RCXCR4 | |
| SCHEMBL31477752 | 0.90 | MC4R (0.83) | MC4RMC5RMC3RMC1RCXCR4 | |
| SCHEMBL29622934 | 0.89 | MC4R (0.83) | MC4RMC5RMC3RMC1RCXCR4 | |
| Giractide SCHEMBL1650268 | 0.88 | MC4R (0.85) | MC4RMC5RMC3RMC1RCXCR4 | |
| SCHEMBL29385997 | 0.88 | MC4R (0.84) | MC4RMC5RMC3RMC1RCXCR4 | |
| SCHEMBL29382991 | 0.88 | MC4R (0.84) | MC4RMC5RMC3RMC1RCXCR4 | |
| Tosactide SCHEMBL29353880 | 0.88 | MC4R (0.77) | MC4RMC5RMC3RMC1RCXCR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240374689-A1 | HIGHLY ACTIVE POLYPEPTIDES AND METHODS OF MAKING AND USING THE SAME | LONGEVITY BIOTECH, INC. | 2024-11-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240374689-A1 | HIGHLY ACTIVE POLYPEPTIDES AND METHODS OF MAKING AND USING THE SAME | SCTR, GIPR, APLNR | MC4R 528/4885MC5R 722/4885MC3R 323/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.